These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25141114)

  • 1. Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis.
    Picon PD; Pribbernow SC; Prompt CA; Schacher SC; Antunes VV; Mentz BP; Oliveira FL; Souza CM; Schacher FC
    Clinics (Sao Paulo); 2014 Aug; 69(8):547-53. PubMed ID: 25141114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.
    Fishbane S; Singh B; Kumbhat S; Wisemandle WA; Martin NE
    Clin J Am Soc Nephrol; 2018 Aug; 13(8):1204-1214. PubMed ID: 29921734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.
    Coyne DW; Singh AK; Lopes RD; Bailey CK; DiMino TL; Huang C; Connaire J; Rastogi A; Kim SG; Orias M; Shah S; Patel V; Cobitz AR; Wanner C
    Clin J Am Soc Nephrol; 2022 Sep; 17(9):1325-1336. PubMed ID: 35918106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients.
    Azmandian J; Abbasi MR; Pourfarziani V; Nasiri AA; Ossareh S; Ezzatzadegan Jahromi S; Sanadgol H; Amini S; Shahvaroughi Farahani A
    Am J Nephrol; 2018; 48(4):251-259. PubMed ID: 30253403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
    Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R
    Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar erythropoietin in anemia treatment (BEAT)-Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study.
    Miao B; Isachkina AN; Shutov EV; Selyutin AA; Kvitkova LV; Shilo VY; Vetchinnikova ON; Alexandrov IV; Perlin DV; Zuev AV; Davydkin IL; Mironova TP; Solovyova OM; Tutin AP; Omelchenko AM; Vareesangthip K; Khadikova NG; Li M; Li X
    Medicine (Baltimore); 2022 Nov; 101(47):e31426. PubMed ID: 36451454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.
    Thadhani R; Guilatco R; Hymes J; Maddux FW; Ahuja A
    Am J Nephrol; 2018; 48(3):214-224. PubMed ID: 30196301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients.
    Harzallah A; Zouaghi K; Dridi A; Boubaker K; Beji S; Ayari M; El Younsi F; Moussa FB; Kheder A
    Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):78-82. PubMed ID: 25579720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study.
    Haag-Weber M; Eckardt KU; Hörl WH; Roger SD; Vetter A; Roth K
    Clin Nephrol; 2012 Jan; 77(1):8-17. PubMed ID: 22185963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Comparison of Renogen, a Biosimilar Epoetin-a, with the Originator, Eprex, in Chronic Kidney Disease Anemia in Indonesia: A Preliminary Study.
    Hustrini NM; Siregar P; Setiawati A; Nugroho P
    Acta Med Indones; 2019 Jul; 51(3):230-237. PubMed ID: 31699946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.
    Dellanna F; Fluck RJ; Lonnemann G; Wild CA; Iwanowitsch A; Meissner R; Audhya P
    Clin Nephrol; 2015 Nov; 84(5):280-8. PubMed ID: 26396097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl.
    Hörl WH; Locatelli F; Haag-Weber M; Ode M; Roth K;
    Clin Nephrol; 2012 Jul; 78(1):24-32. PubMed ID: 22732334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.
    Gertz B; Kes P; Essaian A; Bias P; Buchner A; Zellner D
    Curr Med Res Opin; 2012 Jul; 28(7):1101-10. PubMed ID: 22533679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.